Skip to main content
. 2020 Dec 18;124(5):951–962. doi: 10.1038/s41416-020-01199-4

Fig. 3. Resistance to DDA due to absent SLFN11 can be reversed by inhibition of ATR, WEE1 and CHK, but not other DDRi.

Fig. 3

a Left, HSA synergy scores of the tested gemcitabine-DDRi combinations in DU145 isogenic cells with the indicated drugs (in triplicates for WT and KO1; n = 1 for KO2). Right, representative heatmaps of combination activity in excess of the calculated HSA model. Prexasertib is the CHKi. b, c Response to gemcitabine in DU145 isogenic cells in the absence or presence of 1 µM ATRi (b) and 0.36 µM WEE1i (c) (continuous treatment for 72 h) as determined by CellTiter-Glo® luminescent cell viability assays (n = 3). Data are presented as mean percentages ± s.d. (n = 3) of the DMSO and single-agent DDRi-treated conditions.